Loading...

REGN REGENERON PHARMACEUTICALS INC Capital Structure Changes 8-K Filing

RGNR

RGN

REGENERON PHARMACEUTICALS INC

(REGN)

2026 8-K

Quarterly Earnings Report

Financial Results Impact

Financial Results Report

Financial Update

Financial Results Announced

Financial Update

Financial Statements

Financial Statements

Financial Results

Financial Update

Q3 Earnings Report

Q3 2024 Preview

Earnings Reports

Financial Results

Shareholder Vote Results

Financial Results

Financial Results Announcement

Management Appointments

Corporate Update at Healthc...

Financial Results Announcement

Financial Results

Earnings Reports

Amendment to Bylaws and Sha...

Financial Results Announcement

Management Changes

Financial Results for Q1 2023

External Links:

Regeneron Pharmaceuticals, Inc. expects a charge of approximately $102 million for acquired in-process research and development, impacting earnings per share by about $0.81 for the first quarter of 2026, with the event dated April 8, 2026.

AI Assistant

REGENERON PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.